We use cookies to analyze site traffic and improve your experience.
By accepting, you consent to the use of analytics cookies.

TSN:NYSETyson Foods, Inc. Analysis

Data as of 2026-05-27 - not real-time

$65.13

Latest Price

4/10Risk

Risk Level: Medium

Executive Summary

Tyson Foods posted a Q1 FY2026 revenue increase of 4.4% to $13.65 billion, beating consensus and propelling the stock to a recent high of $68.75. The share price now sits at $65.13, comfortably above the 20‑day SMA of $66.35 and the 50‑day SMA of $64.53, indicating a short‑term bullish bias. The 200‑day SMA of $59.26 remains well below the current price, reinforcing a longer‑term uptrend. Momentum indicators are mixed: the RSI sits at 46.4, suggesting neutral momentum, while the MACD histogram is negative and the signal line is bearish. Volume has been decreasing, but the stock remains above the key support level of $62.05 and below the resistance at $69.48, providing a clear trading range. With a beta of 0.23 and a 30‑day volatility of 28.8%, the equity exhibits low systematic risk despite relatively high price swings.
Valuation metrics appear stretched, as the DCF‑derived fair value of $24.47 is far below the market price, and the trailing PE of 51.3 contrasts with a forward PE of 14.3. The dividend yield of 3.13% is attractive, but the payout ratio of 159% raises concerns about sustainability. Analysts have upgraded Tyson to Overweight with a median price target of $72, indicating expectations for further upside of roughly 9%. The company’s modest revenue growth, thin margins, and high debt‑to‑equity ratio (44%) suggest limited upside beyond earnings acceleration. Considering the low sector risk of Consumer Defensive and a strong balance sheet, the stock’s risk profile is moderate. Overall, the combination of solid earnings momentum, supportive technicals, and a bullish analyst outlook makes Tyson a compelling near‑term buy, while valuation caution tempers longer‑term enthusiasm.

Market Outlook

Short Term

< 1 year
Positive
Model confidence: 7/10

Key Factors

  • Earnings beat and revenue growth
  • Price above short‑term SMA and support level
  • Neutral to bullish technical indicators

Medium Term

1–3 years
Positive
Model confidence: 8/10

Key Factors

  • Analyst upgrade to Overweight with $72‑$75 price target
  • Forward PE of 14.3 indicating earnings upside
  • Attractive dividend yield despite payout concerns

Long Term

> 3 years
Neutral
Model confidence: 6/10

Key Factors

  • DCF fair value far below market price
  • Thin margins and high payout ratio
  • Low beta and defensive sector offsetting valuation risk

Key Metrics & Analysis

Financial Health

Revenue Growth4.40%
Profit Margin0.81%
P/E Ratio51.3
ROE2.62%
ROA2.47%
Debt/Equity44.41
P/B Ratio1.3
Op. Cash Flow$2.1B
Free Cash Flow$1.0B

Technical Analysis

TrendBullish
RSI46.4
Support$62.05
Resistance$69.48
MA 20$66.35
MA 50$64.53
MA 200$59.26
MACDBearish
VolumeDecreasing
Fear & Greed Index91.05

Valuation

Fair Value$24.47
Target Price$71.15
Upside/Downside9.25%
GradeOvervalued
TypeBlend
Dividend Yield3.13%

Risk Assessment

Beta0.23
Volatility28.77%
Sector RiskLow
Reg. RiskMedium
Geo RiskLow
Currency RiskLow
Liquidity RiskMedium

This analysis may contain inaccuracies and is provided for informational and research purposes only. It is not personal investment advice, a recommendation, or an instruction to buy, sell, or hold any asset.